News

  • CROSSJECT unveils its strategic choices and new roadmap

    - Priority given to emergency treatment drugs
    - Priority focus on penetrating the US market
    - Capitalisation on a first-class industry partnership with CENEXI and internalisation of certain manufacturing operations
    - Revision of regulatory timetable: Approval to Market applications filed for 6 products in 2018

    Read the Press release

    Read more
  • Crossject - AFPric study: patients approve needle-free injection

    Crossject and AFPric, the largest French association of patients with polyarthritis and chronic inflammatory rheumatisms, pursued their collaboration and released today the main findings of a study conducted with members of AFPric on their treatment and their interest in needle-free injection. 

    The study reveals that patients with rheumatoid polyarthritis are largely prepared to use needle-free injection as part of their treatment. 85.9% of respondents are ready to use a needle-free injection device, three quarters of which are currently taking their treatment with injection 

    Read the press release

    Read more

Events

  • 01/09/2017

    Crossject will be present at Biomed Event

    Crossject will be present at Biomed Event 2017 in Paris, on January 26th.
    Contact Tim Muller: tm@scientex.eu or  t.muller@crossject.com  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more
  • 01/08/2017

    Crossject will be present at ESN European Conferences 2017

    Crossject will be present at ESN Investors Conference in Paris, on March 30th 2017.
    Contact Tim Muller: tm@scientex.eu or t.muller@crossject.com  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more

video

Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos